Start here if you're new
what it is
Ardent runs hospitals, clinics, and doctor networks that get paid when patients show up for surgeries, scans, checkups, and emergencies.
how it gets paid
Last year Ardent Health made $6.0B in revenue. inpatient hospital care was the main engine at $2.64B, or 44% of sales.
what just happened
Revenue hit $4.7B and EPS reached $0.64, according to the provided EDGAR figures.
At a glance
n/a balance sheet
6.1x trailing p/e — the market's not buying it — or you found a deal
11.0% return on capital — nothing to write home about
$1.58 fy2024 eps est
$6B fy2024 rev est
What they do
Ardent runs hospitals, clinics, and doctor networks that get paid when patients show up for surgeries, scans, checkups, and emergencies.
Ardent wins because your care often stays inside one local system. Healthcare ecosystem (hospitals, clinics, and doctors tied together → one place for most of your care → patients stay, referrals stay, and dollars stay). That network handled about 5.8 million visits for 1.2 million unique patients in 2024 across 30 hospitals and roughly 280 sites of care, according to company data in the provided source set.
How they make money
$6.0B
annual revenue
inpatient hospital care
$2.64B
flat
outpatient and ambulatory care
$1.86B
up
physician services
$0.84B
up
emergency services
$0.42B
flat
other specialty services
$0.24B
up
The products that matter
operates acute care hospitals
hospital operations
core business · tied to the $6.4B–$6.7B outlook
This is the center of gravity. The market is not debating whether hospitals matter. It's debating whether this hospital network can deliver more than the 1–6% growth implied by management's 2026 guide.
cash engine
employs and supports doctors
physician clinics
adjacent network · still has to move group results
Clinics matter because they help keep patient volume inside the system. But when the full company is guiding to just 1–6% growth, this segment is not yet large enough to change the entire story on its own.
volume support
capital return
share repurchases
$50M authorized · about 3.8% of market cap
A $50M buyback can help at the margin because it equals roughly 3.8% of today's market cap. It cannot do the job of organic growth. This is support, not a substitute for execution.
signal, not thesis
Key numbers
6.1x
trailing p/e
P/E (price-to-earnings ratio → how many years of current profit you're paying for → 6.1x says the market does not trust these earnings).
$6.0B
annual revenue
This is a big revenue base for a company worth about $1B, which is why even small margin changes matter.
9.3%
operating margin
Operating margin (profit after running the business → your buffer before debt costs → 9.3% leaves some room, not much).
$2.3B
long-term debt
Debt is more than twice the market cap, which means lenders matter almost as much as shareholders here.
Financial health
n/a
strength
- balance sheet grade n/a
- long-term debt $2.3B (63% of capital)
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for ARDT right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Revenue hit $4.7B and EPS reached $0.64, according to the provided EDGAR figures.
The quarter showed revenue up 199% vs. prior year and EPS up 476% vs. prior year in the provided data. Quiet part out loud: when a stock still trades at 6.1x earnings after numbers like that, the market is questioning how durable the jump is.
$4.7B
revenue
$0.64
eps
9.3%
operating margin
the number that mattered
$0.64 of quarterly EPS matters most because it shows the business can produce real earnings, but the 6.1x trailing P/E says investors are still pricing in slippage.
source: EDGAR filing and provided company data
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
For ARDT, the risk story is specific: you own a hospital operator with $2.3B of debt trying to convince the market that a 1–6% growth guide is conservative, not the new normal.
med
the slowdown could become the baseline
Management guided to just 1–6% growth on $6.4B–$6.7B of expected 2026 revenue. If results keep landing near the low end, the stock will keep trading like a slow-growth operator instead of a rebound story.
Management guided to just 1–6% growth on $6.4B–$6.7B of expected 2026 revenue. If results keep landing near the low end, the stock will keep trading like a slow-growth operator instead of a rebound story.
med
$2.3B of debt leaves less room for bad surprises
Debt equal to 63% of capital is manageable only if execution stays clean. Slower growth and leverage are a bad pair because each makes the other feel heavier.
Debt equal to 63% of capital is manageable only if execution stays clean. Slower growth and leverage are a bad pair because each makes the other feel heavier.
med
the $50M cash flow headwind could crowd out flexibility
A $50M hit is not existential on its own. It matters because ARDT is already balancing a weak guide, a buyback authorization, and a leveraged balance sheet at the same time.
A $50M hit is not existential on its own. It matters because ARDT is already balancing a weak guide, a buyback authorization, and a leveraged balance sheet at the same time.
med
legal noise can make a weak period weaker
A securities class action sits in the background, with a March 9, 2026 lead plaintiff deadline flagged on this page. Lawsuits rarely create the core problem. They can extend a credibility problem once it starts.
A securities class action sits in the background, with a March 9, 2026 lead plaintiff deadline flagged on this page. Lawsuits rarely create the core problem. They can extend a credibility problem once it starts.
You can own a cheap stock with a 6.1x P/E, but with $2.3B of debt and 9.3% operating margin, cheap can stay cheap.
source: institutional data · regulatory filings · risk analysis
Pay attention to
next report
May 6, 2026 earnings
Watch revenue against the full-year $6.4B–$6.7B guide and listen for any change to the $50M cash flow headwind. That is the fastest way to tell whether the selloff was overdone or earned.
trend
whether growth stays stuck near 1–6%
Low single-digit growth is the whole problem. If management starts talking like the current guide is a floor rather than the plan, the stock can breathe. If not, this remains a prove-it story.
capital return
$50M buyback authorization
Announced in November 2025. That's about 3.8% of the current market cap. Useful support if fundamentals stabilize. Cosmetic if they don't.
legal
March 9, 2026 lead plaintiff deadline
The securities class action is not the main investment issue. It is a reminder that sentiment around the stock turned fast after the guidance disappointment.
Analyst rankings
short-term outlook
no published rank
this dataset does not give you a label here, so the guidance matters more than the absent badge
relative safety
no published rank
in human-speak: use the $2.3B debt load and the 11.8% stock reaction as your real-time risk clues
technical setup
no published rank
after an 11.8% post-earnings drop, price action is telling a clearer story than a missing score would
earnings visibility
thin here
that means you should focus on whether May 6 starts rebuilding confidence in the $6.4B–$6.7B outlook
source: institutional data
Institutional activity
institutional ownership data for ARDT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$9
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive